You can buy Luciabro at the lowest price in the online pharmacy Nextgen.ooo . Abrocitinib is an orally available small molecule inhibitor of Janus kinase 1 (JAK1). Janus kinases are intracellular enzymes involved in transduction pathways that regulate hematopoiesis and immune cell function. The Janus kinase (JAK) signal transducer and activator of transcription (STAT) signaling pathway plays a central role in the pathogenesis of various autoimmune and inflammatory diseases. diseases, including atopic dermatitis, a chronic inflammatory skin disease with a complex pathogenesis. Atopic dermatitis is characterized by epidermal hyperplasia, skin barrier dysfunction, and aberrant immune cell activation. Patients with moderate to severe atopic dermatitis report decreased quality of life and often face limited treatment options. JAK inhibitors have recently gained increasing attention as potential treatments for inflammatory diseases, as JAK inhibition is associated with rapid and sustained anti-inflammatory effects.
 
Abrocitinib was approved by the European Commission on December 10, 2021, for the treatment of moderate to severe atopic dermatitis (AD) in adults for whom systemic therapy is indicated. On January 14, 2022, the FDA approved abrocitinib for the treatment of refractory moderate to severe AD in adults whose disease is not adequately controlled with other systemic therapies, including biologics, or when use of these therapies is inappropriate. Health Canada has also approved abrocitinib for use in pediatric patients 12 years of age and older.